Dasatinib efficacy by dosing schedule across individual baseline BCR-ABL mutations in chronic phase chronic myelogenous leukemia (CML-CP) after imatinib failure

被引：0
|
作者：
Hochhaus, A.
Mueller, M.
Cortes, J. E.
Kim, D.
Matlob, Y.
Ploughman, L.
Hughes, T.
机构：
[1] Heidelberg Univ, Med Fak Mannheim, Mannheim, Germany
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Catholic Univ Korea, Seoul, South Korea
[4] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[5] Bristol Myers Squibb, Pennington, NJ USA
[6] Inst Med & Vet Sci, Adelaide, SA 5000, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.7014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] DASATINIB EFFICACY AFTER IMATINIB FAILURE BY DOSING SCHEDULE AND BASELINE BCR-ABL MUTATION STATUS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
    Hochhaus, A.
    Mueller, M. C.
    Cortes, J.
    Kim, D. W.
    Matloub, Y.
    Ploughman, L.
    Hughes, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 371 - 372
  • [2] Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations
    Hochhaus, A.
    Branford, S.
    Radich, J.
    Mueller, M. C.
    Shah, N.
    Erben, P.
    Ernst, T.
    Acevedo, M.
    Nicaise, C.
    Hughes, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations
    Mueller, M. C.
    Branford, S.
    Radich, J.
    Shah, N.
    Erben, P.
    Ernst, T.
    Acevedo, M.
    Nicaise, C.
    Hughes, T.
    Hochhaus, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 127 - 127
  • [4] RESPONSE TO NILOTINIB IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) ACCORDING TO BCR-ABL MUTATIONS AT BASELINE
    Radich, J.
    Kim, D. -W
    Martinelli, G.
    Soverini, S.
    Branford, S.
    Mueller, M.
    Haque, A.
    Shou, Y.
    Hochhaus, A.
    Hughes, T.
    Saglio, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 55 - 55
  • [5] Response to nilotinib in chronic myelogenous leukemia patients in chronic phase (CML-CP) according to BCR-ABL mutations at baseline #7060
    Saglio, G.
    Radich, J.
    Kim, D.
    Martinelli, G.
    Branford, S.
    Mueller, M.
    Soverini, S.
    Shou, Y.
    Hochhaus, A.
    Hughes, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Hochhaus, Andreas
    Kim, Dong-Wook
    Martinelli, Giovanni
    Hughes, Timothy P.
    Soverini, Simona
    Branford, Susan
    Muller, Martin C.
    Erben, Philipp
    Haque, Ariful
    Shou, Yaping
    Saglio, Giuseppe
    Radich, Jerald P.
    BLOOD, 2008, 112 (11) : 1103 - 1104
  • [7] Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations
    Mueller, Martin C.
    Cortes, Jorge
    Kim, Dong-Wook
    Druker, Brian J.
    Erben, Philipp
    Pasquini, Ricardo
    Hughes, Timothy P.
    Matloub, Yousif
    Ploughman, Lynn
    Hochhaus, Andreas
    BLOOD, 2008, 112 (11) : 171 - 172
  • [8] Analysis of Molecular Data and the Emergence of Mutations for Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) Patients Treated with Dasatinib After Imatinib Failure.
    Branford, Susan
    Hochhaus, Andreas
    Mueller, Martin
    Bahceci, Erkut
    Ploughman, Lynn
    Mukhopadhyay, Jaydip
    Hughes, Timothy
    BLOOD, 2009, 114 (22) : 1270 - 1271
  • [9] Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure
    Mueller, M. C.
    Branford, S.
    Radich, J.
    Kim, D. W.
    Martinelli, G.
    Saglio, G.
    Hughes, T.
    Shou, Y.
    Weitzman, A.
    Baccarani, M.
    Hochhaus, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP)
    Cortes, Jorge
    O'Brien, Susan
    Borthakur, Gautam
    Jones, Dan
    Ravandi, Farhad
    Koller, Charles
    Mesina, Ofelia
    Ferrajoli, Alessandra
    Shan, Jianqin
    Kantarjian, Hagop
    BLOOD, 2008, 112 (11) : 74 - 74
12345